Duncan McKechnie - 17 Feb 2026 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
EVP, Chief Commercial Officer
Signature
/s/ Christiana Stevenson, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
17 Feb 2026
Net transactions value
-$555,345
Form type
4
Filing time
19 Feb 2026, 16:21:12 UTC
Previous filing
18 Feb 2026
Next filing
26 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
McKechnie Duncan EVP, Chief Commercial Officer C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON /s/ Christiana Stevenson, Attorney-in-Fact 19 Feb 2026 0002062139

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Award $0 +4,962 +25% $0.000000 24,490 17 Feb 2026 Direct F1
transaction VRTX Common Stock Tax liability $555,345 -1,148 -4.7% $483.75 23,342 17 Feb 2026 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock unit award that vests in installments beginning on February 20, 2027.